Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients

Israel Medical Association Journal

Volumn 6, Issue 4, 2004, Pages 213-217

  Nakhoul, Farid ^a,b   Abassi, Zaid ^b   Plawner, Michal ^a   Khankin, Eli ^a   Ramadan, Rawi ^a   Lanir, Noami ^a   Brenner, Benjamine ^a,b   Green, Jacob ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

B vitamins; Folic acid; Hemodialysis; Homocysteine; Methylenetetrahydrofolate reductase; Vascular access thrombosis diabetes

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LUPUS ANTICOAGULANT; PYRIDOXINE; VON WILLEBRAND FACTOR; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ALLELE; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; GENOTYPE; HEMODIALYSIS PATIENT; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; LIPID ANALYSIS; MUTATIONAL ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOPHILIA; THROMBOSIS; VASCULAR ACCESS; BLOOD; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FOLIC ACID; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME; VITAMIN B 12; VITAMIN B 6;

EID: 2342622053     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Van den Berg M, Boers GHJ, Homocystinuria: what about mild hyperhomocysteinaemia? Postgrad Med J 1996;72:513-18.
2. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997;52:10-20.
3. Sela BA, Doolman R. Dialysis patients and cyclosporine-treated graft recipients: two sectors with high homocysteine levels. Harefauh 1999;136(3):218-22 (Hebrew).
4. Zidek W. Homocysteine - a new arteriosclerotic factor in end-stage renal failure [Edtorial]. Nephron 1997;75:249-50.
5. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
6. Bar-Meir E, George J, Shoenfeld Y. Hyperhomocysteinemia - a risk factor or vascular disease. Harefauh 1999;136(2):129-33 (Hebrew).
7. Sela B. Hyperhomocysteinemia as a risk factor in atherosclerotic and thrombotic vascular processes. Harefauh 1995;129(10):407-12 (Hebrew).
8. 12 and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia. Kidney Int 2001;59:1103-9.
9. Ma KW, Greene KL, Raij L. Cardivascular risk factor in chronic renal failure and hemodialysis populations. Am Kidney Dis 1992;19:505-13.
10. Wilcken DEL, Gupta VJ. Sulphr [sic] containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 1979;9:301-7.
11. Maiorca R, Cancarini GC, Brunori G, Camerini C, Manili L. Morbidity and mortality of CAPD and hemodialysis. Kidney Int 1993;43(Suppl 40):S4-15.
12. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
13. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artert stenosis. N Engl Med 1995;332:286-91.
14. Bostom AG, Shemin D, Lapane KL, et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-52.
15. Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996;94:2743-8.
16. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocysteinemia, factors V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-82.
17. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 1988;37:697-701.
18. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 1996;50(Suppl 57):S11-17.
19. Van Guldener C, Donker AJM, Jakobs C, Teerlink T, de Meer K, Stehouwer CDA. No net renal extraction of homocysteine in fasting humans. Kidney Int 1998;54:166-99.
20. Bostom AG, Culleton B. Hyperhomocysteinemia in chronic renal disease: potential relevance to arteriovascular. Semin Dial 1999;12: 103-11.
21. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-13.
22. Sunder-Plassmann G, Födinger M, Buchmayer H, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna Multicenter Study. J Am Soc Nephrol 2000;11:1106-16.
23. Bostom AG, Shemin D, Lapane KL, et al. Folate status is the major determinant of fasting total plasma homocysteiene levels in maintenance dialysis patients. Atherosclerosis 1996;123:193-202.
24. House AA, Donnelly JG. Effect of multivitamins on plasma homocysteine folate levels in patients on hemodialysis. ASAIO J 1999;45:94-7.
25. Dierkes J, Domrose U, Ambrosch A, Bosselmann HP, Neuman KH, Luley C. Response of hyperhomocysteinemia to folic acid supplementation in patient with end-stage renal disease. Clin Nephrol 1999;5:108-15.